Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia

January 19, 2024

https://www.globenewswire.com/news-release/2024/01/09/2806129/28908/en/Tonix-Pharmaceuticals-Presents-Additional-Data-Highlighting-the-Favorable-Tolerability-and-Differentiated-Side-Effect-Profile-of-TNX-102-SL-in-Second-Positive-Phase-3-Clinical-Tria.html

Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia
As previously announced, Phase 3 RESILIENT study of TNX-102 SL met its primary endpoint (p=0.00005) with statistically significant and clinically...
https://www.globenewswire.com/news-release/2024/01/09/2806129/28908/en/Tonix-Pharmaceuticals-Presents-Additional-Data-Highlighting-the-Favorable-Tolerability-and-Differentiated-Side-Effect-Profile-of-TNX-102-SL-in-Second-Positive-Phase-3-Clinical-Tria.html

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.